{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:29:49Z","timestamp":1792790989599,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"7th youth science foundation of the First Hospital of Jilin University","id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The traditional chemotherapy, including Adriamycin (Doxorubicin, DOX), is widely used and is part of the first-line chemotherapy of invasive B cell lymphoma. DOX is nonselective cytotoxic drug and has many adverse effects, which limit its clinical application in combination with other anti-cancer drugs. Optimization of the delivery system targeting tumor microenvironment could be a feasible approach that may have significant clinical significance. Further, combination of DOX with other anticancer drugs, such as curcumin, can enhance the synergistic effects, possibly through epigenetic mechanisms. Hence, we evaluated the efficacy and toxicity of novel nanoparticles that enable the co-delivery of DOX and curcumin in the treatment of invasive B cell lymphoma both\n                    <jats:italic>in vivo<\/jats:italic>\n                    and vitro. The polymer nano materials [mPEG-b-P(Glu-co-Phe)] was used to co-load DOX and curcumin (CUR): L-DOX\u2009+\u2009CUR. DOX signal was measured to determine the ability of the drugs entering the cells by flow cytometry, and the different enrichment areas in the cells were directly observed by confocal microscope. The toxicity of LDOX\u2009+\u2009CUR was tested by CCK-8 assay in different cells, and the synergistic coefficients were calculated. The cell apoptosis and the possible mechanisms of apoptosis pathways regulation by L-DOX\u2009+\u2009CUR were examined using flow cytometry and Western Blot. The MTD (maximum tolerable dose) test was performed in mice. Tumor-bearing SCID mice (i.e., BJAB cell) were used to evaluate the\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy of L-DOX\u2009+\u2009CUR. L-DOX\u2009+\u2009CUR, was prepared successfully, and the mole ratio of DOX and CUR fixed in 1.0:1.2. (DOX loading rate 9.7%, CUR loading rate 8.1%). L-DOX\u2009+\u2009CUR exhibited increased intracellular delivery and the main enrichment area of DOX was nucleus. L-DOX\u2009+\u2009CUR increased cytotoxicity, induced higher rates of apoptosis, and had synergistic effect, especially in BJAB cells (min CI 0.019). It even had epigenetic effect and affected miRNA levels favorably by down-regulating miR-21, miR-199a and up-regulating miR-98 and miR-200c. Additionally, L-DOX\u2009+\u2009CUR increased MTD in Kunming mice (i.e., 25\u2009mg\/kg), compared to DOX (10\u2009mg\/kg) and L-DOX (20\u2009mg\/kg). In BJAB cell bearing SCID mice, L-DOX\u2009+\u2009CUR treatment suppressed tumor growth compared to DOX or L-DOX alone, and exhibited less weight loss in mice. We developed new polymer nanoparticles-mPEG-b-P (Glu-co-Phe) co-loaded with DOX and DUR. L-DOX\u2009+\u2009CUR exhibited synergistic cytotoxic and apoptotic effects on invasive B cell lymphoma. Treatment of L-DOX\u2009+\u2009CUR potentiated tumor killing in xenografts and reduced toxicity\n                    <jats:italic>in vivo<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-64828-1","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:08:48Z","timestamp":1589263728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"64828_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/wnan.43","volume":"1","author":"S Bisht","year":"2009","unstructured":"Bisht, S. & Maitra, A. Dextran-doxorubicin\/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip. reviews. Nanomed. nanobiotechnology 1, 415\u2013425 (2009).","journal-title":"Wiley Interdiscip. reviews. Nanomed. nanobiotechnology"},{"key":"64828_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1349-7006.2009.01103.x","volume":"100","author":"Y Matsumura","year":"2009","unstructured":"Matsumura, Y. & Kataoka, K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100, 572\u2013579 (2009).","journal-title":"Cancer Sci."},{"key":"64828_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/156652413804486179","volume":"13","author":"M Gupta","year":"2013","unstructured":"Gupta, M., Agrawal, G. P. & Vyas, S. P. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting. Curr. Mol. Med. 13, 179\u2013204 (2013).","journal-title":"Curr. Mol. Med."},{"key":"64828_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","volume":"71","author":"H Maeda","year":"2009","unstructured":"Maeda, H., Bharate, G. Y. & Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. pharmaceutics biopharmaceutics : Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 71, 409\u2013419 (2009).","journal-title":"Eur. J. pharmaceutics biopharmaceutics : Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"64828_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.biomaterials.2007.09.029","volume":"29","author":"M Deng","year":"2008","unstructured":"Deng, M. et al. Miscibility and in vitro osteocompatibility of biodegradable blends of poly[(ethyl alanato) (p-phenyl phenoxy) phosphazene] and poly(lactic acid-glycolic acid). Biomaterials 29, 337\u2013349 (2008).","journal-title":"Biomaterials"},{"key":"64828_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.biomaterials.2007.09.029","volume":"29","author":"M Deng","year":"2008","unstructured":"Deng, M. et al. Miscibility and in vitro osteocompatibility of biodegradable blends of poly [(ethyl alanato)(p-phenyl phenoxy) phosphazene] and poly (lactic acid-glycolic acid). Biomaterials 29, 337\u2013349 (2008).","journal-title":"Biomaterials"},{"key":"64828_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157\u2013170 (2013).","journal-title":"J. Pharm. Pharmacol."},{"key":"64828_CR8","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1016\/j.actbio.2013.08.015","volume":"9","author":"S Lv","year":"2013","unstructured":"Lv, S. et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta biomaterialia 9, 9330\u20139342 (2013).","journal-title":"Acta biomaterialia"},{"key":"64828_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.fct.2011.01.021","volume":"49","author":"L Hosseinzadeh","year":"2011","unstructured":"Hosseinzadeh, L. et al. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem. Toxicol. : an. Int. J. published Br. Ind. Biol. Res. Assoc. 49, 1102\u20131109 (2011).","journal-title":"Food Chem. Toxicol. : an. Int. J. published Br. Ind. Biol. Res. Assoc."},{"key":"64828_CR10","doi-asserted-by":"publisher","first-page":"1980763","DOI":"10.1155\/2016\/1980763","volume":"2016","author":"L Junkun","year":"2016","unstructured":"Junkun, L. et al. Curcumin Downregulates Phosphate Carrier and Protects against Doxorubicin Induced Cardiomyocyte Apoptosis. Biomed. Res. Int. 2016, 1980763 (2016).","journal-title":"Biomed. Res. Int."},{"key":"64828_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/cdd.2014.36","volume":"21","author":"JQ Kwong","year":"2014","unstructured":"Kwong, J. Q. et al. Genetic deletion of the mitochondrial phosphate carrier desensitizes the mitochondrial permeability transition pore and causes cardiomyopathy. Cell Death Differ. 21, 1209\u20131217 (2014).","journal-title":"Cell Death Differ."},{"key":"64828_CR12","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini, N. & Kardami, E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8, 46663\u201346680 (2017).","journal-title":"Oncotarget"},{"key":"64828_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.onc.1210600","volume":"27","author":"S Alcal\u00e1","year":"2008","unstructured":"Alcal\u00e1, S., Klee, M., Fern\u00e1ndez, J., Fleischer, A. & Pimentel-Mui\u00f1os, F. X. A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 27, 44 (2008).","journal-title":"Oncogene"},{"key":"64828_CR14","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.1038\/sj.onc.1208864","volume":"24","author":"S Uddin","year":"2005","unstructured":"Uddin, S. et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 24, 7022\u2013703 (2005).","journal-title":"Oncogene"},{"key":"64828_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/13543776.2017.1339793","volume":"27","author":"RMC Di Martino","year":"2017","unstructured":"Di Martino, R. M. C., Bisi, A., Rampa, A., Gobbi, S. & Belluti, F. Recent progress on curcumin-based therapeutics: a patent review (2012\u20132016). Part II: curcumin derivatives in cancer and neurodegeneration. Expert. Opin. Ther. Pat. 27, 953\u2013965 (2017).","journal-title":"Expert. Opin. Ther. Pat."},{"key":"64828_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/13543776.2017.1276566","volume":"27","author":"RM Di Martino","year":"2017","unstructured":"Di Martino, R. M. et al. Recent progress on curcumin-based therapeutics: a patent review (2012\u20132016). Part I: Curcumin. Expert. Opin. Ther. Pat. 27, 579\u2013590 (2017).","journal-title":"Expert. Opin. Ther. Pat."},{"key":"64828_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1208\/s12248-015-9811-z","volume":"17","author":"MM Yallapu","year":"2015","unstructured":"Yallapu, M. M., Nagesh, P. K., Jaggi, M. & Chauhan, S. C. Therapeutic Applications of Curcumin Nanoformulations. AAPS J. 17, 1341\u20131356 (2015).","journal-title":"AAPS J."},{"key":"64828_CR18","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2147\/DDDT.S129008","volume":"11","author":"LR Tefas","year":"2017","unstructured":"Tefas, L. R. et al. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. Drug. Des. Devel Ther. 11, 1605\u20131621 (2017).","journal-title":"Drug. Des. Devel Ther."},{"key":"64828_CR19","doi-asserted-by":"publisher","first-page":"022001","DOI":"10.1088\/1748-6041\/4\/2\/022001","volume":"4","author":"P Bawa","year":"2009","unstructured":"Bawa, P., Pillay, V., Choonara, Y. E. & Du Toit, L. C. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater. 4, 022001 (2009).","journal-title":"Biomed. Mater."},{"key":"64828_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jphotobiol.2016.02.032","volume":"158","author":"D Agudelo","year":"2016","unstructured":"Agudelo, D., Bourassa, P., Berube, G. & Tajmir-Riahi, H. A. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity. J. Photochem. Photobiol. B 158, 274\u2013279 (2016).","journal-title":"J. Photochem. Photobiol. B"},{"key":"64828_CR21","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho, C. et al. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 16, 3267\u20133285 (2009).","journal-title":"Curr. Med. Chem."},{"key":"64828_CR22","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1021\/acs.molpharmaceut.7b00606","volume":"14","author":"Q Zhai","year":"2017","unstructured":"Zhai, Q. et al. Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier. Mol. Pharm. 14, 3888\u20133895 (2017).","journal-title":"Mol. Pharm."},{"key":"64828_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar, S. An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther. 10, 853\u2013858 (2014).","journal-title":"J. Cancer Res. Ther."},{"key":"64828_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jphp.12539","volume":"68","author":"AM Meredith","year":"2016","unstructured":"Meredith, A. M. & Dass, C. R. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J. Pharm. Pharmacol. 68, 729\u2013741 (2016).","journal-title":"J. Pharm. Pharmacol."},{"key":"64828_CR25","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/mabi.201200145","volume":"12","author":"W Song","year":"2012","unstructured":"Song, W. et al. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol. Biosci. 12, 1514\u20131523 (2012).","journal-title":"Macromol. Biosci."},{"key":"64828_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.exphem.2005.12.015","volume":"34","author":"J Skommer","year":"2006","unstructured":"Skommer, J., Wlodkowic, D. & Pelkonen, J. Cellular foundation of curcumin-induced apoptosis in follicular lymphoma cell lines. Exp. Hematol. 34, 463\u2013474 (2006).","journal-title":"Exp. Hematol."},{"key":"64828_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep30962","volume":"6","author":"K Nagahama","year":"2016","unstructured":"Nagahama, K. et al. Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. Sci. Rep. 6, 30962 (2016).","journal-title":"Sci. Rep."},{"key":"64828_CR28","doi-asserted-by":"publisher","first-page":"e57218","DOI":"10.1371\/journal.pone.0057218","volume":"8","author":"M Shakibaei","year":"2013","unstructured":"Shakibaei, M. et al. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. PLoS One 8, e57218 (2013).","journal-title":"PLoS One"},{"key":"64828_CR29","first-page":"1050","volume":"21","author":"A Unlu","year":"2016","unstructured":"Unlu, A., Nayir, E., Dogukan Kalenderoglu, M., Kirca, O. & Ozdogan, M. Curcumin (Turmeric) and cancer. J. BUON 21, 1050\u20131060 (2016).","journal-title":"J. BUON"},{"key":"64828_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/13543780802594593","volume":"18","author":"S Uddin","year":"2009","unstructured":"Uddin, S., Khan, A. S. & Al-Kuraya, K. S. Developing curcumin into a viable therapeutic for lymphoma. Expert. Opin. investigational drugs 18, 57\u201367 (2009).","journal-title":"Expert. Opin. investigational drugs"},{"key":"64828_CR31","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","volume":"66","author":"LP Swift","year":"2006","unstructured":"Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R. & Cutts, S. M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 66, 4863\u20134871 (2006).","journal-title":"Cancer Res."},{"key":"64828_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3109\/13880209.2014.914233","volume":"53","author":"D Dangkong","year":"2015","unstructured":"Dangkong, D. & Limpanasithikul, W. Effect of citral on the cytotoxicity of doxorubicin in human B-lymphoma cells. Pharm. Biol. 53, 262\u2013268 (2015).","journal-title":"Pharm. Biol."},{"key":"64828_CR33","first-page":"84","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang, F., Teves, S. S., Kemp, C. J., Henikoff, S. & Doxorubicin, D. N. A. torsion, and chromatin dynamics. Biochim. Biophys. Acta 1845, 84\u201389 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"64828_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3109\/03602532.2011.609174","volume":"43","author":"V Hanusova","year":"2011","unstructured":"Hanusova, V., Bousova, I. & Skalova, L. Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug. Metab. Rev. 43, 540\u2013557 (2011).","journal-title":"Drug. Metab. Rev."},{"key":"64828_CR35","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1021\/am5090226","volume":"7","author":"A Mallick","year":"2015","unstructured":"Mallick, A. et al. Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl. Mater. Interfaces 7, 7584\u20137598 (2015).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"64828_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1568011054866964","volume":"5","author":"SM Cutts","year":"2005","unstructured":"Cutts, S. M., Swift, L. P., Rephaeli, A., Nudelman, A. & Phillips, D. R. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr. Med. Chem. Anticancer. Agents 5, 431\u2013447 (2005).","journal-title":"Curr. Med. Chem. Anticancer. Agents"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64828-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:28:36Z","timestamp":1670304516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64828"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64828-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7832"}}